Endocrine Abstracts

Background: One of the main drawbacks of primary treatment of Graves’ disease (GD) with thionamide drugs (TD) is the high relapse rate estimated to be 50–60%. Fear about side effects, specially agranulocitosis and hepatic complications, is other drawback of this treatment option.Objective: To evaluate the clinical and/or biochemical characteristics that might predict relapse in patients with GD treated with TD.Design and ...